Brief: CelltrionShows Promising Results In Phase III Study Of Ct-P47, Biosimilar Candidate Of Roactemra In Patients With Rheumatoid Arthritis
13/06/2024 23:15
June 13 (Reuters) - Celltrion Inc 068270.KS :
* CELLTRION:SHOWS PROMISING RESULTS IN PHASE III STUDY OF
CT-P47,
BIOSIMILAR CANDIDATE OF ROACTEMRA IN PATIENTS WITH RHEUMATOID
ARTHRITIS AT EULAR 2024
* CELLTRION- CT-P47 HIGHLY SIMILAR IN TERMS OF EFFICACY &
SAFETY
TO REFERENCE PRODUCT ROACTEMRA FOR TREATMENT OF RHEUMATOID
ARTHRITIS UP TO WEEK 32
* CELLTRION INC -CT-P47 AI WAS WELL TOLERATED, AND NO NEW
SAFETY
SIGNALS WERE FOUND IN STUDY
Source text for Eikon: ID:nBw9J4pf2a
Further company coverage: 068270.KS
((Reutersbriefs@thomsonreuters.com;))
Recent news on Celltrion
See all newsBrief: Celltrion Inc To Acquire 100 Billion Won Worth Of Own Shares
Brief: Celltrion Q1 Operating. Profit 322 Billion Won, Up 115% Y/Y
Brief: Celltrion To Cancel 100 Billion Won Treasury Shares
Brief: Celltrion Plans Phase 3 Clinical Trials For Keytruda Biosimilar With 220 Patients
Brief: Celltrion To Buy 100 Billion Won Of Own Shares